![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ENDOCRINE AND DIABETES
Discovery Research Laboratory II, R&D, Kissei Pharmaceutical Co., Ltd., Azumino, Japan
The low-affinity sodium glucose cotransporter (SGLT2), which is expressed specifically in the kidney, plays a major role in renal glucose reabsorption in the proximal tubule. We have discovered sergliflozin, a prodrug of a novel selective SGLT2 inhibitor, based on benzylphenol glucoside. In structure, it belongs to a new category of SGLT2 inhibitors and its skeleton differs from that of phlorizin, a nonselective SGLT inhibitor. We investigated its pharmacological properties and potencies in vitro and in vivo. By examining a Chinese hamster ovary-K1 cell line stably expressing either human SGLT2 or human high-affinity sodium glucose cotransporter (SGLT1), we found sergliflozin-A (active form) to be a highly selective and potent inhibitor of human SGLT2. At pharmacological doses, sergliflozin, sergliflozin-A, and its aglycon had no effects on facilitative glucose transporter 1 activity, which was inhibited by phloretin (the aglycon of phlorizin). The transport maximum for glucose in the kidney was reduced by sergliflozin-A in normal rats. As a result of this effect, orally administered sergliflozin increased urinary glucose excretion in mice, rats, and dogs in a dose-dependent manner. In an oral glucose tolerance test in diabetic rats, sergliflozin exhibited glucose-lowering effects independently of insulin secretion. Any glucose excretion induced by sergliflozin did not affect normoglycemia or electrolyte balance. These data indicate that selective inhibition of SGLT2 increases urinary glucose excretion by inhibiting renal glucose reabsorption. As a representative of a new category of antidiabetic drugs, sergliflozin may provide a new and unique approach to the treatment of diabetes mellitus.
Address correspondence to: Dr. Masayuki Isaji, Central Research Laboratories, Kissei Pharmaceutical Co., Ltd., 4365-1, Hotaka, Azumino, Nagano, 399-8304, Japan. E-mail: masayuki_isaji{at}pharm.kissei.co.jp
This article has been cited by other articles:
|
|
 |
|
  J. Calado, Y. Sznajer, D. Metzger, A. Rita, M. C. Hogan, A. Kattamis, M. Scharf, V. Tasic, J. Greil, F. Brinkert, et al. Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion Nephrol. Dial. Transplant., July 12, 2008; (2008) gfn386v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Han, D. L. Hagan, J. R. Taylor, L. Xin, W. Meng, S. A. Biller, J. R. Wetterau, W. N. Washburn, and J. M. Whaley Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats Diabetes, June 1, 2008; 57(6): 1723 - 1729. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Pajor, K. M. Randolph, S. A. Kerner, and C. D. Smith Inhibitor Binding in the Human Renal Low- and High-Affinity Na+/Glucose Cotransporters J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 985 - 991. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vernaleken, M. Veyhl, V. Gorboulev, G. Kottra, D. Palm, B.-C. Burckhardt, G. Burckhardt, R. Pipkorn, N. Beier, C. van Amsterdam, et al. Tripeptides of RS1 (RSC1A1) Inhibit a Monosaccharide-dependent Exocytotic Pathway of Na+-D-Glucose Cotransporter SGLT1 with High Affinity J. Biol. Chem., September 28, 2007; 282(39): 28501 - 28513. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
